Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAlexion Pharmaceuticals, Inc.
About this trial
The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.
Eligibility criteria
Qualifiers
History of a positive serologic test for anti-AChR antibodies, and
History of abnormal neuromuscular transmission test demonstrated by singlefibre electromyography or repetitive nerve stimulation
History of positive anticholinesterase test (e.g., edrophonium chloride test); or
Patient demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician
Disqualifiers
Patient unable to understand and sign the informed consent
Hypersensitivity to the active substance or to any of the excipients of the study product
Patient for whom the study product is contraindicated according to SmPC
Previous treatment with C5 inhibitors
Trial design
Treatments tested in this trial
- Ravulizumab
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov